Sign In
Buy CAR
$173.86
+1.48 (+0.86%)
At Close: Jun 03, 2026
Multiplexed-engineered, iPSC-derived CAR T Cell Targets Proteins Expressed on Cancer Cells in Response to Cellular Stress and Malignant Transformation
Canadian Apartment Properties Real Estate Investment Trust (CDPYF) Q3 2024 Earnings Call Transcript
03:24pm, Friday, 08'th Nov 2024
Canadian Apartment Properties Real Estate Investment Trust (OTC:CDPYF) Q3 2024 Earnings Conference Call November 8, 2024 9:00 AM ET Company Participants Nicole Dolan - IR Mark Kenney - President and C
Canadian Apartment Properties: Immigration Changes Spook Investors
12:04pm, Friday, 08'th Nov 2024
We had downgraded CAPREIT to a hold in September as valuation looked average. The stock has dropped sharply, and two factors are to blame. We examine the setup and give you our outlook.
New preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM) and enhanced potency to better target solid tumors will be presented at SITC Additional profiling of patient
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), will share 18 presentations, including six oral presentations, demonstrating the strength of its CAR T-cell therapy portfo
Why Avis Budget Stock Soared 17% After Earnings
12:44pm, Friday, 01'st Nov 2024
Avis Budget didn't grow earnings in 2024, but 2025 looks better.
Avis Budget Group, Inc. (CAR) Q3 2024 Earnings Call Transcript
11:17am, Friday, 01'st Nov 2024
Avis Budget Group, Inc. (NASDAQ:CAR ) Q3 2024 Earnings Conference Call November 1, 2024 8:30 AM ET Company Participants David Calabria - SVP, Corporate Finance and Treasurer Joe Ferraro - President an
CARsgen® U.S. Clinical Holds Lifted by FDA
09:33pm, Thursday, 31'st Oct 2024
SHANGHAI , Oct. 31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies
Compared to Estimates, Avis Budget (CAR) Q3 Earnings: A Look at Key Metrics
07:31pm, Thursday, 31'st Oct 2024
The headline numbers for Avis Budget (CAR) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street e
Avis Budget Group (CAR) Q3 Earnings and Revenues Miss Estimates
06:20pm, Thursday, 31'st Oct 2024
Avis Budget Group (CAR) came out with quarterly earnings of $6.65 per share, missing the Zacks Consensus Estimate of $8.55 per share. This compares to earnings of $16.78 per share a year ago.
Avis's stock slides after third-quarter earnings fall short of estimates
04:43pm, Thursday, 31'st Oct 2024
Avis Budget Group's stock was falling in after-hours trade Thursday, after the car-rental company's third-quarter earnings fell short of estimates.
Avis Budget Group Reports Third Quarter Results
04:00pm, Thursday, 31'st Oct 2024
PARSIPPANY, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced financial results for third quarter 2024 today.
Avis Budget Group to Announce Third Quarter 2024 Results on October 31st
03:10pm, Friday, 25'th Oct 2024
PARSIPPANY, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced today that it plans to report its third quarter 2024 results after the market close on Thursday, Oct
Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth
09:24am, Friday, 25'th Oct 2024
Lyell Immunopharma, Inc.'s financials show reduced losses and efficient cash management, with a strong cash position supporting operations through 2027 despite a challenging biotech environment. The c
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
04:00pm, Thursday, 24'th Oct 2024
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL) announced today that it has entered into a definitive agreement to acquire ImmPACT Bio USA Inc. (
